Supplement Scoop: FDA Wants Your Label Lowdown
Published Date: 2/24/2026
Notice
Summary
The FDA wants to hear from companies that make, package, label, or store dietary supplements about their current manufacturing rules. They’re asking for feedback on how they collect information to make sure supplements are safe and high-quality. If you’re involved in dietary supplements, you’ve got until April 27, 2026, to share your thoughts—no extra costs, just your voice!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Major Recordkeeping Burden for Supplement Makers
Dietary supplement businesses must follow 21 CFR part 111 recordkeeping across many areas (personnel, sanitation, equipment, production controls, quality control, components/packaging, batch records, complaints, etc.). FDA estimates the total annual recordkeeping burden at 929,140 hours (including 279,120 hours for quality control records under §111.140, 279,120 hours for components/packaging records under §111.180, and 204,160 hours for batch production records under §111.260). The Agency also states there are no capital or operating and maintenance costs associated with this collection.
Option to Reduce 100% Ingredient Testing
Under 21 CFR 111.75(a)(1), a manufacturer that currently performs 100% identity testing of incoming dietary ingredients may petition the FDA (under 21 CFR 10.30) to request an exemption to reduce the testing frequency if it demonstrates no material diminution of assurance. FDA estimates the reporting burden for such a petition as 1 response taking 8 hours.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03588 — Hearing Designation Order Issued to 97.5 Licensee TX, LLC
The FCC is holding a hearing about 97.5 Licensee TX, LLC’s request to transfer control of three El Paso radio stations. They’re checking if the current owner followed the rules, if an unauthorized transfer happened, and if everyone involved is honest and qualified. If you want to join the hearing, you must act by March 26, 2026—this could affect who runs these stations and how they operate.
Next: 2026-03590 — Agency Information Collection Activity Under OMB Review: Bus Testing Program
The Federal Transit Administration is asking for public feedback on its Bus Testing Program paperwork by March 26, 2026. This affects bus manufacturers and testers who provide info to make sure buses are safe and reliable. The goal is to keep the process clear and easy while following government rules—no big cost changes, just smoother info collection.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in